share_log
Breakings ·  Jan 8 21:24

The stock price of Avadel Pharmaceuticals (AVADEL) fell over 20% in Post-Market Trading, and the company expects its revenue for the fourth quarter to be approximately 50 million, while the market estimates it at 52.312 million.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment